Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia

NCT01198067 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped \<75% participant accrual

Conditions

Recurrent Waldenstrom Macroglobulinemia
Refractory Waldenstrom Macroglobulinemia

Interventions

DRUG: Pomalidomide

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]